iBio, Inc. (IBIO) stock
IBIONasdaqPharmaceutical PreparationsFiscal year ends June 30
$0.75+0.04 (+5.86%)
Close on Nov 17, 2026Market cap $48.11MP/E –Yield –
iBio r&d expenses
Research and development expenses are spending on new products and technology.
iBio's R&D Expenses for the twelve months ending Sep 30, 2026 was $22.74M, up 115.4% year over year. For fiscal 2026 it was $19.64M, up 136.3% from the year before. Over ten years it grew 20.1% a year on average. The highest annual figure on record is $19.64M in fiscal 2026.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $19.64M | +136.3% |
| FY2025 | Jun 30, 2025 | $8.31M | +60.3% |
| FY2024 | Jun 30, 2024 | $5.19M | -49.8% |
| FY2023 | Jun 30, 2023 | $10.33M | +5.1% |
| FY2022 | Jun 30, 2022 | $9.83M | -1.6% |
| FY2021 | Jun 30, 2021 | $9.99M | +179.6% |
| FY2020 | Jun 30, 2020 | $3.57M | -34.7% |
| FY2019 | Jun 30, 2019 | $5.47M | +37.3% |
| FY2018 | Jun 30, 2018 | $3.99M | -3.2% |
| FY2017 | Jun 30, 2017 | $4.12M | +30.4% |
| FY2016 | Jun 30, 2016 | $3.16M | -9.7% |
| FY2015 | Jun 30, 2015 | $3.50M | +84.1% |
| FY2014 | Jun 30, 2014 | $1.90M | -44.7% |
| FY2013 | Jun 30, 2013 | $3.43M | -31.1% |
| FY2012 | Jun 30, 2012 | $4.98M | +61.5% |
| FY2011 | Jun 30, 2011 | $3.08M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | $6.65M | +87.3% |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $8.56M | +165.5% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $3.25M | +70.7% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $4.28M | +128.0% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $3.55M | +172.0% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $3.22M | +182.8% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $1.91M | +110.8% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $1.88M | +22.3% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $1.31M | -18.7% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $1.14M | -51.6% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $904.00K | -65.8% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $1.54M | -44.8% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $1.61M | -37.0% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $2.36M | -33.9% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $2.64M | -19.2% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $2.78M | -10.3% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $2.55M | +17.9% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $3.56M | +50.0% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $3.27M | +75.7% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $3.10M | +431.2% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $2.16M | +97.4% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $2.37M | +167.3% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $1.86M | +90.6% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $583.00K | -64.1% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $1.10M | -24.6% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $888.00K | -30.2% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $977.00K | -13.1% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $1.62M | +55.9% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $1.45M | +50.4% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $1.27M | +28.2% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $1.12M | +14.1% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $1.04M | -6.3% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $966.00K | -15.0% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $993.00K | -5.3% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $985.00K | +20.1% |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $1.11M | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $1.14M | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $1.05M | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $820.00K | – |
See a number that looks wrong?